MX2015015434A - Corroles dirigidas para toxicidad tumoral y rm. - Google Patents
Corroles dirigidas para toxicidad tumoral y rm.Info
- Publication number
- MX2015015434A MX2015015434A MX2015015434A MX2015015434A MX2015015434A MX 2015015434 A MX2015015434 A MX 2015015434A MX 2015015434 A MX2015015434 A MX 2015015434A MX 2015015434 A MX2015015434 A MX 2015015434A MX 2015015434 A MX2015015434 A MX 2015015434A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- disclosed
- mri
- targeted corrole
- corrole nanoparticle
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Radiology & Medical Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se divulgan composiciones que comprenden nanopartículas corrole dirigidas; y un excipiente aceptable. También, se divulgan composiciones que comprenden nanopartículas corrole dirigidas; y un vehículo aceptable. Además, se divulgan en este documento los métodos de formación de imágenes de la afección de un sujeto, que comprenden proporcionar una composición que comprende una nanopartícula corrole dirigida; a administración de una cantidad efectiva de la nanopartícula corrole dirigida al sujeto; y la formación de imágenes de la afección el sujeto. Además, en lo sucesivo se divulgan métodos para tratar el cáncer en un sujeto, que comprenden una composición que comprende una nanopartícula corrole; y la administración de una dosis terapéuticamente eficaz de la nanopartícula corrole dirigida al sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361821106P | 2013-05-08 | 2013-05-08 | |
PCT/US2014/037234 WO2014182868A1 (en) | 2013-05-08 | 2014-05-08 | Targeting corroles for tumor toxicity and mri |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015015434A true MX2015015434A (es) | 2016-03-15 |
Family
ID=51864925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015015434A MX2015015434A (es) | 2013-05-08 | 2014-05-08 | Corroles dirigidas para toxicidad tumoral y rm. |
Country Status (17)
Country | Link |
---|---|
US (2) | US9757386B2 (es) |
EP (2) | EP2993983B1 (es) |
JP (1) | JP6640715B2 (es) |
KR (1) | KR20160008523A (es) |
CN (2) | CN108451930A (es) |
AU (2) | AU2014262653B2 (es) |
CA (1) | CA2910030A1 (es) |
DK (1) | DK2993983T3 (es) |
ES (1) | ES2791043T3 (es) |
HK (1) | HK1221870A1 (es) |
IL (1) | IL265935B (es) |
MX (1) | MX2015015434A (es) |
PL (1) | PL2993983T3 (es) |
PT (1) | PT2993983T (es) |
RU (1) | RU2674146C2 (es) |
WO (1) | WO2014182868A1 (es) |
ZA (1) | ZA201508092B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009009441A2 (en) | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
PL2880160T3 (pl) | 2012-08-03 | 2019-03-29 | Cedars-Sinai Medical Center | Izolowanie wzmacniających transport mutantów białka dostarczającego lek |
US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
MX2016009284A (es) | 2014-01-17 | 2016-10-07 | Cedars Sinai Medical Center | Construcciones dirigidas a receptor y sus usos. |
US9850293B2 (en) | 2014-04-04 | 2017-12-26 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle |
EP3687998A4 (en) * | 2017-08-31 | 2021-05-19 | Technion Research & Development Foundation Limited | CORROL COMPOSITIONS |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA129822A (en) | 1910-08-24 | 1910-12-13 | The John Bertram And Sons Company, Limited | Motor controlling apparatus |
CA140995A (en) | 1912-03-05 | 1912-06-11 | Davydd C. Hughes | Type plate mechanism |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
WO2002094318A1 (en) | 2001-05-18 | 2002-11-28 | University Of Southern California | Vector for targeted delivery to cells |
WO2003004021A1 (en) * | 2001-07-02 | 2003-01-16 | Technion Research And Development Foundation Ltd. | Method for the preparation of selectively-substituted corroles and new substituted corroles |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
WO2009009441A2 (en) | 2007-07-06 | 2009-01-15 | Cedars-Sinai Medical Center | Self-assembling complex for targeting chemical agents to cells |
AU2008293376B2 (en) | 2007-08-28 | 2013-07-11 | Technion Research & Development Foundation Ltd. | Transition metal complexes of corroles for preventing cardiovascular diseases or disorders |
CA2751058A1 (en) * | 2008-01-31 | 2009-08-06 | Technion Research And Development Foundation Ltd | Corroles for neuroprotection and neurorescue |
WO2009151539A1 (en) | 2008-05-24 | 2009-12-17 | Sirnaomics, Inc. | COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS |
WO2010078517A2 (en) | 2008-12-31 | 2010-07-08 | Sirnaomics, Inc. | Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer |
WO2010085665A2 (en) | 2009-01-23 | 2010-07-29 | Cedars-Sinai Medical Center | Targeted delivery system |
CN101704820A (zh) * | 2009-09-24 | 2010-05-12 | 江苏大学 | 三(4-氯苯基)咔咯化合物及其合成方法 |
WO2011094335A2 (en) | 2010-01-26 | 2011-08-04 | Yale University | Microrna signatures predicting responsiveness to anti-her2 therapy |
MX2014001823A (es) * | 2011-08-15 | 2014-08-21 | Technion Res & Dev Foundation | Combinaciones de corroles y estatinas. |
PL2880160T3 (pl) | 2012-08-03 | 2019-03-29 | Cedars-Sinai Medical Center | Izolowanie wzmacniających transport mutantów białka dostarczającego lek |
US9757386B2 (en) | 2013-05-08 | 2017-09-12 | Cedars-Sinai Medical Center | Targeting corroles for tumor toxicity and MRI |
MX2016009284A (es) | 2014-01-17 | 2016-10-07 | Cedars Sinai Medical Center | Construcciones dirigidas a receptor y sus usos. |
US9850293B2 (en) | 2014-04-04 | 2017-12-26 | Cedars-Sinai Medical Center | Targeting trastuzumab-resistant HER2+ breast cancer with a HER3-targeting nanoparticle |
KR20190013929A (ko) | 2016-05-27 | 2019-02-11 | 세다르스-신나이 메디칼 센터 | 약물-전달 나노입자 및 약물 내성암에 대한 치료 |
-
2014
- 2014-05-08 US US14/272,610 patent/US9757386B2/en active Active
- 2014-05-08 CN CN201810246983.5A patent/CN108451930A/zh not_active Withdrawn
- 2014-05-08 CN CN201480025009.6A patent/CN105307499B/zh not_active Expired - Fee Related
- 2014-05-08 KR KR1020157030349A patent/KR20160008523A/ko not_active Application Discontinuation
- 2014-05-08 AU AU2014262653A patent/AU2014262653B2/en not_active Ceased
- 2014-05-08 MX MX2015015434A patent/MX2015015434A/es unknown
- 2014-05-08 EP EP14794410.2A patent/EP2993983B1/en active Active
- 2014-05-08 WO PCT/US2014/037234 patent/WO2014182868A1/en active Application Filing
- 2014-05-08 EP EP20157304.5A patent/EP3730155A1/en not_active Withdrawn
- 2014-05-08 RU RU2015152033A patent/RU2674146C2/ru active
- 2014-05-08 PT PT147944102T patent/PT2993983T/pt unknown
- 2014-05-08 PL PL14794410T patent/PL2993983T3/pl unknown
- 2014-05-08 JP JP2016513057A patent/JP6640715B2/ja not_active Expired - Fee Related
- 2014-05-08 ES ES14794410T patent/ES2791043T3/es active Active
- 2014-05-08 CA CA2910030A patent/CA2910030A1/en not_active Abandoned
- 2014-05-08 DK DK14794410.2T patent/DK2993983T3/da active
-
2015
- 2015-11-02 ZA ZA2015/08092A patent/ZA201508092B/en unknown
-
2016
- 2016-08-25 HK HK16110127.7A patent/HK1221870A1/zh unknown
-
2017
- 2017-06-15 US US15/624,228 patent/US10709801B2/en active Active
-
2018
- 2018-10-17 AU AU2018250401A patent/AU2018250401B2/en not_active Ceased
-
2019
- 2019-04-10 IL IL265935A patent/IL265935B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
RU2674146C2 (ru) | 2018-12-07 |
HK1221870A1 (zh) | 2017-06-16 |
ZA201508092B (en) | 2017-02-22 |
AU2014262653B2 (en) | 2018-07-26 |
PT2993983T (pt) | 2020-05-22 |
JP2016526021A (ja) | 2016-09-01 |
DK2993983T3 (da) | 2020-05-18 |
US20140335025A1 (en) | 2014-11-13 |
AU2014262653A1 (en) | 2015-11-12 |
WO2014182868A1 (en) | 2014-11-13 |
IL265935A (en) | 2019-05-30 |
CN105307499A (zh) | 2016-02-03 |
RU2015152033A3 (es) | 2018-04-25 |
CA2910030A1 (en) | 2014-11-13 |
CN108451930A (zh) | 2018-08-28 |
IL265935B (en) | 2020-06-30 |
EP2993983A1 (en) | 2016-03-16 |
US10709801B2 (en) | 2020-07-14 |
EP3730155A1 (en) | 2020-10-28 |
US20170281802A1 (en) | 2017-10-05 |
EP2993983B1 (en) | 2020-03-25 |
EP2993983A4 (en) | 2017-01-11 |
AU2018250401A1 (en) | 2018-11-08 |
PL2993983T3 (pl) | 2020-09-07 |
CN105307499B (zh) | 2018-04-27 |
AU2018250401B2 (en) | 2020-06-11 |
ES2791043T3 (es) | 2020-10-30 |
JP6640715B2 (ja) | 2020-02-05 |
KR20160008523A (ko) | 2016-01-22 |
RU2015152033A (ru) | 2017-06-16 |
US9757386B2 (en) | 2017-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015015434A (es) | Corroles dirigidas para toxicidad tumoral y rm. | |
MY166014A (en) | Combination therapy methods for treating proliferative diseases | |
NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
PH12016502066A1 (en) | Methods of treating bladder cancer | |
MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
NZ738929A (en) | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy | |
MX2017007321A (es) | Terapias de combinacion. | |
MX2016007851A (es) | Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos. | |
PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
MX2016007826A (es) | Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco. | |
MX2015003643A (es) | Metodo para tratar el cancer. | |
NZ705910A (en) | Pyrrolobenzodiazepines and conjugates thereof | |
MX2016004441A (es) | Tratamiento del cancer con una combinacion de plinabulina y taxano. | |
EP4140487A8 (en) | Combination therapy for treating cancer | |
PH12015502536A1 (en) | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging | |
EA201591924A1 (ru) | Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10 | |
MD4643C1 (ro) | Noi compuşi de indolizină, procedeu de obţinere a lor şi compoziţii farmaceutice care le conţin | |
MX2018007823A (es) | Terapia de combinacion de bromodominio e inhibidor de proteina extra terminal. | |
PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
MY189663A (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
WO2013052158A3 (en) | Targeted nanovectors and their use for treatment of brain tumors | |
MX2021001832A (es) | Conjugados para su uso en metodos de tratamiento del cancer. |